CAPVAXIVE 4 ug/.5mL

CAPVAXIVE 4 ug/0.5mL is a pneumococcal 21-valent conjugate vaccine designed for intramuscular administration. This vaccine helps protect against pneumococcal diseases caused by 21 serotypes. Learn more about its uses and effects.

CAPVAXIVE is a pneumococcal 21-valent conjugate vaccine used to prevent pneumococcal diseases. It targets 21 serotypes of the Streptococcus pneumoniae bacteria, which can cause infections like pneumonia, meningitis, and sepsis. This vaccine is typically administered to individuals who are at higher risk of pneumococcal infections, such as those with weakened immune systems or certain chronic health conditions. The primary use of CAPVAXIVE is to provide immunity against these serious infections, helping to reduce the risk of complications.

Common effects of CAPVAXIVE may include mild to moderate reactions at the injection site, such as redness, swelling, or pain. Some individuals may experience systemic effects like fever, fatigue, or muscle aches. These effects are generally temporary and resolve within a few days. Severe allergic reactions are rare but possible and require immediate medical attention.

CAPVAXIVE should be administered by healthcare professionals trained in vaccination procedures. It is important to inform your healthcare provider about any allergies, especially to any components of the vaccine. Individuals with a history of severe allergic reactions to previous pneumococcal vaccines should exercise caution. Always follow the recommended storage and handling guidelines to maintain the vaccine's efficacy.

CAPVAXIVE may interact with other medications or vaccines. It is generally recommended to avoid receiving other vaccines simultaneously unless advised by a healthcare provider. Alcohol and certain medications that affect the immune system may influence the vaccine's effectiveness. Always consult with a healthcare professional before taking any new medications or supplements while undergoing vaccination.